Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Crossref DOI link: https://doi.org/10.1007/s12282-017-0826-4
Published Online: 2018-01-04
Published Print: 2018-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pivot, Xavier http://orcid.org/0000-0003-3689-5013
Im, Seock Ah
Guo, Matthew
Marmé, Frederik
Funding for this research was provided by:
Eisai Inc.
License valid from 2018-01-04